

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.  
applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
  
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8



Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 14:05:59 ON 08 APR 2008





```

chain nodes :
11 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-12 3-15 4-16 8-13 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
3-15 4-16 5-7 6-9 7-8 8-9 8-13
exact bonds :
2-12 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:O,CN,X,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS  
12:CLASS 13:Atom 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,CN,X,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:06:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 51890 TO ITERATE

100.0% PROCESSED 51890 ITERATIONS

205 ANSWERS

SEARCH TIME: 00.00.01

L2 205 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 14:06:42 ON 08 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 8 Apr 2008 VOL 148 ISS 15  
FILE LAST UPDATED: 7 Apr 2008 (20080407/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2 full

L3           7 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:192157 CAPLUS

DOCUMENT NUMBER: 148:262585

TITLE: Preparation of azabenzimidazole derivatives as prodrug inhibitors of fructose 1,6-bisphosphatase

INVENTOR(S): Reddy, Raja K.; Erion, Mark D.; Dang, Qun

PATENT ASSIGNEE(S): Metabasis Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 112pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008019309	A1	20080214	WO 2007-US75159	20070803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:


US 2006-835693P P 20060804

OTHER SOURCE(S): MARPAT 148:262585


GI




I



II



III




IV

AB Azabenzimidazole derivs. I-III wherein G1-G5 and G7 are independently C, N; g6 is C; A and L and E are H, substituted N, NO2, substituted O, substituted S, substituted amide, halo, acyl, sulfonyl, guanidine, C(NH)-substituted N, NH-sulfonyl, sulfonamide, CN, sulfoxide, perhalo-acyl, perhalo-alkyl, perhalo-alkoxy, alkyl, alkenyl, alkynyl,

alicyclic; together A and L form cyclic group; J is H, substituted N, NO<sub>2</sub>, substituted O, substituted S, substituted amide, halo, acyl, sulfonyl, guanidine, C(NH)-substituted N, NH-sulfonyl, sulfonamide, CN, sulfoxide, perhalo-acyl, perhalo-alkyl, perhalo-alkoxy, alkyl, halo-alkyl, aminoalkyl, alkenyl, alkynyl, alicyclic, aryl, aralkyl; E and J together form a cyclic group; J and D together form a cyclic group; D is H, substituted N, substituted O, substituted amide, acyl, sulfonyl, alkyl, alkenyl, alkynyl; D and X together form a cyclic group; X is alkylamino-, -alkylene(hydroxy)-, -alkylene(carboxy)-, -alkylene-(phosphonate)-, -alkylene-, -alkenylene-, -alkynylene-, -alkylene (sulfonate)-, -arylene-, -carbonyl-alkyl-, -(1,1-dihalo)alkylene-, -aminocarbonylamino-, -alkylamino-alkyl-, -alkoxyalkyl-, -alkylthio-alkyl-, -alkylthio-, -alkylaminocarbonyl-, -alkylcarbonylamino-, -alicyclic-, -aralkyl-, -alkylaryl-; M is substituted phosphate, were prepared and tested as inhibitors of fructose 1,6-bisphosphatase. Thus, title azabenzimidazole IV was prepared and tested in rats as fructose 1,6-bisphosphatase inhibitor. Title compds. tested in rats demonstrated inhibition of gluconeogenesis. A method of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of insulin resistance, is reported.

IT 1006693-00-0P 1006693-01-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of azabenzimidazole derivs. as prodrug inhibitors of fructose 1,6-bisphosphatase)  
 RN 1006693-00-0 CAPLUS  
 CN Phosphonic acid, P-[5-(6-chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-furanyl]- (CA INDEX NAME)



RN 1006693-01-1 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED  
 \*\*\* SUBSTANCE INFORMATION NOT AVAILABLE \*\*\*  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:191744 CAPLUS

DOCUMENT NUMBER: 148:262855

TITLE: Preparation of carbocyclic purine nucleoside analogs as antitumor agents and inhibitors of E1 activating enzymes

INVENTOR(S): Claiborne, Christopher F.; Critchley, Stephen; Langston, Steven P.; Olhava, Edward J.; Peluso, Stephane; Weatherhead, Gabriel S.; Vyskocil, Stepan; Visiers, Irache; Mizutani, Hiro; Cullis, Courtney  
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 204pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008019124	A1	20080214	WO 2007-US17463	20070806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080051404	A1	20080228	US 2007-890338	20070806
PRIORITY APPLN. INFO.:			US 2006-836158P	P 20060808
OTHER SOURCE(S):	MARPAT 148:262855			

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Nucleoside derivs. I, wherein A is 6-membered nitrogen-containing heteroaryl ring, optionally fused to a 5- or 6-membered aryl, heteroaryl, cyclo-aliphatic or heterocyclic ring; W is -CH-, -CHF-, -CF2-, -CH(R')-, -CF(R')-, -NH-, -N(R')-, -O-, -S-, or -NHC(O)-; R' is aliphatic, fluoro-aliph, alkylene chain that is attached to a ring position on ring A to form a 5-, 6-, or 7-membered fused ring, wherein the alkylene chain optionally is substituted with Cl, aliphatic, fluoro-aliphatic, O, -CN, or amide; X is CH2, CHF, CF2, NH, O; Y is O, S, substituted carbon; each R is independently H, F, aliphatic, fluoro-aliphatic; two R, taken together with the carbon atom to which they are attached, form a 3- to 6-membered carbocyclic ring; or one R, taken together with R1 and the intervening carbon atoms, forms a 3- to 6-membered spiro-cyclic ring; or two R together form O; R1 is H, or aliphatic; R and R1 taken together with the intervening carbon atoms form a 3- to 6-membered spiro-cyclic ring; R2 and R5 are independently is H, F, CN, N3, OH, alkoxy, substituted hydrazine, carbamate, amide, acyl, oxy-amide, ester, oxy-carboxylate, fluoro-aliphatic, aliphatic; R3 is H, F, aliphatic, fluoro-aliphatic; R4 is H, F, aliphatic, fluoro-aliphatic; R6 is H, aliphatic; n is 1-3; were prepared as



inhibitors of E1 activating enzymes and useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. Thus, carbocyclic nucleoside analog II was prepared and tested in vitro and in mice as inhibitor of E1 activating enzyme. The compds. are designed to be inhibitors of Nedd8-activating enzyme (APBP1-Uba3) (NAE), ubiquitin activating enzyme (UAE), and/or activating enzyme (Aos1-Uba2) (SAE).

IT 1007124-30-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbocyclic purine nucleoside analogs as antitumor agents and inhibitors of E1 activating enzymes)

RN 1007124-30-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1279258 CAPLUS  
 DOCUMENT NUMBER: 148:45110  
 TITLE: Hit generation and exploration: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases  
 AUTHOR(S): Bavetsias, Vassilios; Sun, Chongbo; Boulloc, Nathalie; Reynisson, Johannes; Workman, Paul; Linardopoulos, Spiros; McDonald, Edward  
 CORPORATE SOURCE: Department of Chemistry, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cancer Research UK Laboratory, Surrey, SM2 5NG, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(23), 6567-6571  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



I

AB A hit generation and exploration approach led to the discovery of 31 (2-(4-(6-chloro-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide) (I), a potent, novel inhibitor of Aurora-A, Aurora-B and Aurora-C kinases with IC50 values of 0.042, 0.198 and 0.227  $\mu$ M, resp. Compound 31 inhibits cell proliferation and has good microsomal stability.  
 IT 960122-06-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (imidazopyridine derivs. as inhibitors of Aurora kinases)  
 RN 960122-06-9 CAPLUS  
 CN Benzenamine, 4-(6,7-dichloro-3H-imidazo[4,5-b]pyridin-2-yl)-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT:

25

THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:817587 CAPLUS

DOCUMENT NUMBER: 147:211880

TITLE: Preparation of imidazopyridine derivatives as protein kinase inhibitors for the treatment of diabetes, obesity, dementia, cancer, and inflammation

INVENTOR(S): Lee, Seung Chul; Choi, Jin Seok; Oh, Jung Hoon; Park, Boonsaeng; Kim, Yong Eun; Lee, Jun Hee; Shin, Dongkyu; Kim, Cheol Min; Hyun, Young-Lan; Lee, Cheol Soon; Cho, Joong-Myung; Ro, Seonggu

PATENT ASSIGNEE(S): Crystalgenomics, Inc., S. Korea

SOURCE: PCT Int. Appl., 157pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007083978	A1	20070726	WO 2007-KR393	20070123
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
KR 2007077468	A	20070726	KR 2007-7182	20070123
PRIORITY APPLN. INFO.:			KR 2006-6834	A 20060123
			US 2006-846411P	P 20060921

OTHER SOURCE(S): MARPAT 147:211880

GI



AB Title compds. I [wherein R1 = OH, halo, alkyl, etc.; R2 = H, (un)substituted alkyl, aryl, etc.; R3 - R5 = H, (un)substituted alkyl, cycloalkyl, etc.; R2 and R3 may link together to form a ring] and pharmaceutically acceptable salts, hydrates, solvates or isomers thereof were prepared as protein kinase inhibitors. For instance, successive nitro reduction of 4-methyl-3-nitropyridin-2-amine, cyclocondensation of the resultant diamine with benzoic acid to imidazopyridine, oxidation of the Me group with KMnO4 and esterification in methanol, hydrolysis of the

obtained Me ester, and EDC-mediated coupling with 4-acetylphenethylamine led to amide II. This product showed inhibition of glycogen synthase kinase-3 (GSK-3) with an IC50 of 0.02  $\mu$ M. Inhibitory activity of representative I against other protein kinases, including aurora kinase A, extracellular signal-regulated kinase 1 (ERK-1), cyclin-dependent kinase 2 (CDK-2), c-Jun N-terminal kinase 1 (JNK-1), pyruvate dehydrogenase kinase 1 (PDK-1), kinase insert domain protein receptor (KDR) and p38 mitogen-activated protein kinase (MAPK), was also demonstrated. Therefore, the invented compds. and pharmaceutical compns. are useful for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation.


IT 944741-02-0P 944741-03-1P 944741-04-2P  
944741-05-3P 944742-41-0P 944742-92-1P  
944743-61-7P 944743-62-8P 944745-47-5P  
944745-74-8P 944745-79-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridine derivs. as protein kinase inhibitors for treatment of diabetes, obesity, dementia, cancer, and inflammation)


RN 944741-02-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, N-[4-(benzoylamino)phenyl]-6-bromo-2-phenyl- (CA INDEX NAME)




RN 944741-03-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-phenyl- (CA INDEX NAME)




RN 944741-04-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-phenyl-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 944741-05-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-chloro-N-[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]-2-phenyl- (CA INDEX NAME)




RN 944742-41-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[3-(4,5-dichloro-1H-imidazol-1-yl)propyl]-2-(3-furanyl)- (CA INDEX NAME)




RN 944742-92-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(3-thienyl)- (CA INDEX NAME)



RN 944743-61-7 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 944743-62-8 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-chloro-N-[2-(2-chloro-4-pyridinyl)ethyl]-2-(4-fluorophenyl)- (CA INDEX NAME)






RN 944745-47-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-(3-methoxyphenyl)-N-(4-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 944745-74-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-2-(3-fluorophenyl)-N-(4-methyl-3-pyridinyl)- (CA INDEX NAME)



RN 944745-79-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 6-bromo-N-(4-ethoxy-6-methyl-3-pyridinyl)-2-(3-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:996177 CAPLUS  
 DOCUMENT NUMBER: 141:424193  
 TITLE: Imidazo- and thiazolopyridines as JAK3 kinase inhibitors  
 INVENTOR(S): Hemmerling, Martin; Klingstedt, Tomas  
 PATENT ASSIGNEE(S): AstraZeneca AB, Sweden.  
 SOURCE: PCT Int. Appl., 44 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099204	A1	20041118	WO 2004-SE694	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004236144	A1	20041118	AU 2004-236144	20040506
AU 2004236144	B2	20080214		
CA 2524624	A1	20041118	CA 2004-2524624	20040506
EP 1625126	A1	20060215	EP 2004-731525	20040506
EP 1625126	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010081	A	20050516	BR 2004-10081	20040506
CN 1784402	A	20060607	CN 2004-80012617	20040506
JP 2006525997	T	20061116	JP 2006-508045	20040506
EP 1887007	A2	20080213	EP 2007-119970	20040506
EP 1887007	A3	20080326		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 384061	T	20080215	AT 2004-731525	20040506
IN 2005DN04774	A	20071207	IN 2005-DN4774	20051019
MX 2005PA12025	A	20060203	MX 2005-PA12025	20051108
US 20060287355	A1	20061221	US 2005-556228	20051109
PRIORITY APPLN. INFO.:			SE 2003-1373	A 20030506
			EP 2004-731525	A3 20040506
			WO 2004-SE694	W 20040506

OTHER SOURCE(S): MARPAT 141:424193  
 GI



AB Title compds. I [Y = NH, S, O; Ar = (un)substituted Ph; R1 = (un)substituted Ph, 5-7-membered heteroarom.] were prepared for use as JAK3 kinase inhibitors with IC50 < 25  $\mu$ M. Thus, 7-hydroxy-2-methylthiothiazolo[5,4-b]pyridine-6-carboxylic acid was converted to its amide, aminated with 2-EtC6H4NH2, oxidized to the sulfone in two steps, and treated with MeONa to give I [Y = S, Ar = 2-EtC6H4, R1 = OMe].


IT 796088-60-3P 796088-61-4P 796088-63-6P  
 796088-64-7P 796088-65-8P 796088-66-9P  
 796088-67-0P 796088-68-1P 796088-69-2P  
 796088-70-5P 796088-71-6P 796088-72-7P  
 796088-73-8P 796088-74-9P 796088-75-0P  
 796088-76-1P 796088-77-2P 796088-78-3P  
 796088-79-4P 796088-80-7P 796088-81-8P  
 796088-82-9P 796088-83-0P 796088-84-1P  
 796088-85-2P 796088-86-3P 796088-87-4P  
 796088-88-5P 796088-89-6P 796088-90-9P  
 796088-91-0P 796088-92-1P 796088-93-2P  
 796088-94-3P 796088-95-4P 796088-96-5P  
 796088-97-6P 796088-98-7P 796088-99-8P  
 796089-00-4P 796089-01-5P 796089-02-6P  
 796089-03-7P 796089-04-8P 796089-05-9P  
 796089-06-0P 796089-07-1P 796089-08-2P  
 796089-09-3P 796089-10-6P 796089-11-7P  
 796089-12-8P 796089-13-9P 796089-14-0P  
 796089-15-1P 796089-16-2P 796089-17-3P  
 796089-18-4P 796089-19-5P 796089-20-8P  
 796089-21-9P 796089-22-0P 796089-23-1P  
 796089-24-2P 796089-25-3P 796089-26-4P  
 796089-27-5P 796089-28-6P 796089-29-7P  
 796089-30-0P 796089-31-1P 796089-32-2P  
 796089-33-3P 796089-34-4P 796089-35-5P  
 796089-36-6P 796089-37-7P 796089-38-8P  
 796089-39-9P 796089-40-2P 796089-41-3P  
 796089-42-4P 796089-43-5P 796089-44-6P  
 796089-45-7P 796089-46-8P 796089-47-9P  
 796089-48-0P 796089-49-1P 796089-50-4P  
 796089-58-2P 796089-59-3P 796089-66-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo- and thiazolopyridines as JAK3 kinase inhibitors)


RN 796088-60-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)



RN 796088-61-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-63-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-(dimethylamino)phenyl]-7-[(2-ethylphenyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 796088-62-5

CMF C23 H24 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 796088-64-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-65-8 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-66-9 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 2-(3,4-dihydroxyphenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-67-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 2-(3-cyanophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-68-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 2-[(2-cyanophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-69-2 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-70-5 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 2-(3,4-difluorophenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-71-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-(3-chloro-4-hydroxyphenyl)-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 796088-72-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 796088-73-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)






RN 796088-74-9 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-(acetylamino)phenyl]-7-[(2-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 796088-75-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-76-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-[(2-hydroxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 796088-77-2 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-78-3 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 796088-79-4 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-80-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethyl-3-(hydroxymethyl)phenyl)amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-81-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-82-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-83-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethoxy]phenyl]-7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 796088-84-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796088-85-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-86-3 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxypropyl)amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796088-87-4 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxypropyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-88-5 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-89-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-90-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[2,3-dihydroxypropyl]amino]methyl]-2-ethylphenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796088-91-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-92-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

RN 796088-93-2 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796088-94-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796088-95-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[3-(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 796088-96-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 796088-97-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[ (2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796088-98-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[ (1S,2S)-2-(hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796088-99-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[ (2S)-2-(hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-00-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-01-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-02-6 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidinyl)methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA

INDEX NAME)




RN 796089-03-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[1-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-04-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[4-(methylsulfonyl)phenyl]methyl]amino]methyl]phenyl]amino]-2-[4-(2-hydroxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-05-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)-

(9CI) (CA INDEX NAME)




RN 796089-06-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-07-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-08-2 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-09-3 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-10-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-11-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)ethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-12-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-13-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-14-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-15-1 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-16-2 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-hydroxycyclohexyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-17-3 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-18-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-19-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidinyl)methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-20-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 796089-21-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[[2-ethyl-3-[[[4-(methylsulfonyl)phenyl]methyl]amino]methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 796089-22-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[[2-ethyl-3-[[[2-(4-morpholinyl)phenyl]amino]methyl]phenyl]amino]-2-(4-(4-morpholinyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 796089-23-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 796089-24-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-25-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-26-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-27-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-28-6 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[4-(2-hydroxyethyl)-1-piperazinyl)methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-29-7 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[3-(2-hydroxyethyl)-1-piperidinyl)methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796089-30-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-31-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-32-2 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 796089-33-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[2-hydroxycyclohexyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-34-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[[(1R,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 796089-35-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-36-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-piperidinyl)methyl]phenyl]amino]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 796089-37-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxypropyl)amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-38-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-39-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(1H-imidazol-1-ylmethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-40-2 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[3-[(2,3-dihydroxypropyl)amino]methyl]-2-ethylphenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)





RN 796089-41-3 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[[2-ethyl-3-(4-morpholinylmethyl)phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-42-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[[3-[[[(1S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]methyl]-2-ethylphenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-43-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[[2-ethyl-3-[[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-44-6 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-45-7 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S)-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-46-8 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 796089-47-9 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 796089-48-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[2-(hydroxycyclohexyl)amino]methyl]phenyl]amino]-2-(4-pyridinyl)]- (9CI) (CA INDEX NAME)




RN 796089-49-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[3-(hydroxy-1-piperidinyl)methyl]phenyl]amino]-2-(4-pyridinyl)]- (9CI) (CA INDEX NAME)




RN 796089-50-4 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[[[1-(hydroxymethyl)-2-methylpropyl]amino]methyl]phenyl]amino]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 796089-58-2 CAPLUS

CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[(2-ethylphenyl)amino]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 796089-59-3 CAPLUS


CN 1H-imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 796089-66-2 CAPLUS  
 CN 1H-Imidazo[4,5-b]pyridine-6-carboxamide, 7-[[2-ethyl-3-(hydroxymethyl)phenyl]amino]-2-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 796088-60-3  
 CMF C22 H21 N5 O2



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:162689 CAPLUS

DOCUMENT NUMBER: 140:199327

TITLE: Preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis

INVENTOR(S): Johansson, Henrik; Lawitz, Karolina; Nikitidis, Grigorios; Sjöe, Peter; Storm, Peter

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016611	A1	20040226	WO 2003-SE1279	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495511	A1	20040226	CA 2003-2495511	20030813
AU 2003251272	A1	20040303	AU 2003-251272	20030813
EP 1539759	A1	20050615	EP 2003-788216	20030813
EP 1539759	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013461	A	20050705	BR 2003-13461	20030813
CN 1684964	A	20051019	CN 2003-823193	20030813
JP 2006503010	T	20060126	JP 2004-529004	20030813
NZ 538156	A	20060929	NZ 2003-538156	20030813
AT 370138	T	20070915	AT 2003-788216	20030813
ES 2290538	T3	20080216	ES 2003-788216	20030813
ZA 2005000887	A	20060222	ZA 2005-887	20050131
MX 2005PA01581	A	20050425	MX 2005-PA1581	20050209
US 20050261333	A1	20051124	US 2005-524204	20050210
NO 2005001265	A	20050512	NO 2005-1265	20050311
PRIORITY APPLN. INFO.:			SE 2002-2462	A 20020814
			WO 2003-SE1279	W 20030813

OTHER SOURCE(S): MARPAT 140:199327

GI



I



II

AB The use of imidazopyridines (shown as I; variables defined below; e.g. II trifluoroacetate) and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compds. I, together with processes for their preparation, compns. containing them and their use in therapy are also disclosed.

For I: R3 = halogen, CN, C1-3-alkyl or C1-3-alkoxy; Ar = Ph, a 5-6-membered heteroarom. ring or an indole ring, said heteroarom. ring incorporating 1 to 3 O, N and S; R1 = H, halogen, CN, C1-6-alkyl, NO2, SO2Me, C1-6-alkynyl, CH2OH, OR2, (CH2)nNR4R5 or Ph (un)substituted by NH2; m = 1-2 and when m = 2, each R1 may be selected independently; n = 0 or 1; R10 = H, halogen, CN, C1-4-alkyl, C1-4-alkoxy, NR14R15 or a group -X-Y-Z (X = O, S, a bond or NR16 wherein R16 = H or C1-4-alkyl; Y = C1-4-alkyl or a bond; Z = Ph, naphthyl or a 5- or 6-membered heteroarom. ring, a 5- or 6-membered saturated heterocyclic ring containing 1-2 heteroatoms = O, N and

S, or

C3-6-cycloalkyl); addnl. details are given in the claims. Methods of preparation are claimed and >250 example preps. of I are included. For example, II was prepared by condensing 4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)aniline with 4-methoxybenzenesulfonyl chloride in pyridine. In another example, 5-bromo-2,3-diaminopyridine was cyclized with 4-hydroxybenzaldehyde in DMF in the presence of iron(III) chloride hexahydrate to give 65% 4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenol. In another example, N-benzyl-5-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine bis(trifluoroacetate) was prepared in 3 steps starting with cyclization of 2,3-diamino-5-bromopyridine with 6-chloronicotinic acid in the presence of polyphosphoric acid (53%) followed by chlorination using POCl3 to give 44% 6-bromo-2-(6-chloropyridin-3-yl)-3H-imidazo[4,5-b]pyridin-2-amine followed by condensation with benzylamine (51%). Compds. of Examples 1 to 278 gave IC50 values for inhibition of Itk activity of <25  $\mu$ M, e.g. 0.26  $\mu$ M for II.

IT


662116-65-6P, 6,7-Dichloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662116-73-6P, N-Benzyl-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-74-7P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-75-8P 662116-81-6P, 6-Chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine trifluoroacetate 662116-89-4P, 2-[Benzyl[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-

b]pyridin-7-yl]amino]ethanol 662116-93-0P, N-Benzyl-6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662117-13-7P, 7-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile 662117-18-2P, 6,7-Dichloro-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]-1H-imidazo[4,5-b]pyridine 662117-21-7P, 2-Amino-5-(6-chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)phenol 662117-23-9P, 4-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-nitrophenol 662117-24-0P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-nitrophenol 662117-35-3P, 2-(4-Aminophenyl)-6-chloro-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine 662117-41-1P, 6-Bromo-7-methyl-2-(4-nitrophenyl)-1H-imidazo[4,5-b]pyridine 662117-42-2P, 4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)aniline

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis)


RN 662116-65-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-73-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 662116-74-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 662116-75-8 CAPLUS




CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-, bis(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 662116-73-6

CMF C25 H26 Cl N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 662116-81-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 662116-80-5

CMF C26 H28 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662116-89-4 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 662116-93-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 662117-13-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carbonitrile, 7-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-18-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 662117-21-7 CAPLUS

CN Phenol, 2-amino-5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI)  
(CA INDEX NAME)




RN 662117-23-9 CAPLUS

CN Phenol, 4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-nitro- (9CI)  
(CA INDEX NAME)



RN 662117-24-0 CAPLUS


CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-nitro- (9CI)  
(CA INDEX NAME)



RN 662117-35-3 CAPLUS


CN 1H-imidazo[4,5-b]pyridin-7-amine, 2-(4-aminophenyl)-6-chloro-N-phenyl-

(9CI) (CA INDEX NAME)




RN 662117-41-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine, 6-bromo-7-methyl-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 662117-42-2 CAPLUS

CN Benzenamine, 4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



IT 662116-68-9P, 6-Chloro-N-(2-methoxyphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine  
662116-69-0P, 2-[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenol 662116-70-3P, 6-Chloro-N-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine  
662116-72-5P, 6-Chloro-N-cyclopentyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine  
662116-80-5P, 6-Chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine  
662116-84-9P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-7-amine 662116-85-0P, [3-[6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]methanol 662116-86-1P, 6-Chloro-N-(2-fluorophenyl)-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridin-7-amine 662116-87-2P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-phenyl-1H-imidazo[4,5-b]pyridin-7-amine  
662116-88-3P, 6-Chloro-N-(3-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine


662116-90-7P, 2-[Benzyl[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol bis(trifluoroacetate) 662116-91-8P, 2-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol 662116-92-9P, 2-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]ethanol bis(trifluoroacetate) 662116-94-1P, 6-Chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-95-2P, 7-(Benzythio)-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridine 662116-96-3P, 7-(Benzythio)-6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridine bis(trifluoroacetate) 662116-97-4P, 6-Chloro-N-[4-(methylsulfonyl)phenyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-98-5P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[4-(4-morpholinyl)phenyl]-1H-imidazo[4,5-b]pyridin-7-amine 662116-99-6P, N'-[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-N,N-diethyl-1,4-benzenediamine 662117-00-2P, N-[4-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]acetamide 662117-01-3P, N-[4-[[6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]acetamide bis(trifluoroacetate) 662117-02-4P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenoxy-1H-imidazo[4,5-b]pyridine 662117-04-6P, 6-Chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[2-(1-pyrrolidinyl)ethoxy]-1H-imidazo[4,5-b]pyridine 662117-05-7P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-[2-(morpholin-4-yl)ethyl]-3H-imidazo[4,5-b]pyridin-7-amine 662117-07-9P, 6-Chloro-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-(1-phenylethyl)-3H-imidazo[4,5-b]pyridin-7-amine 662117-12-6P, 2-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6,7-dicarbonitrile 662117-14-8P, 7-Anilino-2-[4-[2-[(2-methoxyethyl)(methyl)amino]ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile 662117-19-3P, 5-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]aniline 662117-25-1P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[[[(2R)-pyrrolidin-2-yl)methyl]amino]phenol 662117-26-2P, 5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[[[(2R)-pyrrolidin-2-yl)methyl]amino]phenol bis(trifluoroacetate) 662117-28-4P, [5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(morpholin-4-yl)ethoxy]phenyl]][(2R)-pyrrolidin-2-yl)methyl]amine 662117-30-8P, 4-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-N'-(2-(morpholin-4-yl)ethyl)benzene-1,2-diamine 662117-31-9P, [5-(6-Chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-(4-methylpiperazin-1-yl)phenyl]amine 662117-33-1P, 6,7-Dichloro-2-[4-(4-morpholinyl)phenyl]-1H-imidazo[4,5-b]pyridine 662117-34-2P, [5-(6,7-Dichloro-3H-imidazo[4,5-b]pyridin-2-yl)-2-(morpholin-4-yl)phenyl]amine 662117-38-6P, N-[4-(6,7-Dichloro-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-[2-(morpholin-4-yl)ethyl]amine 662117-40-0P, 6-Bromo-7-methyl-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662117-43-3P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyanobenzenesulfonamide 662117-44-4P 662117-45-5P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide 662117-46-6P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide bis(trifluoroacetate) 662117-47-7P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]quinoline-8-sulfonamide 662117-48-8P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]quinoline-8-sulfonamide bis(trifluoroacetate) 662117-49-9P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide 662117-50-2P,

N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide trifluoroacetate 662117-51-3P,  
N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)benzenesulfonamide 662117-52-4P,  
N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)benzenesulfonamide trifluoroacetate 662117-54-6P,  
N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl-1H-imidazole-4-sulfonamide trifluoroacetate 662117-55-7P,  
N-[4-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide 662117-56-8P, N-[4-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide trifluoroacetate 662117-58-0P, 6-Chloro-2-[4-[[2-(morpholin-4-yl)ethyl]amino]phenyl]-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine 662117-59-1P, 6-Chloro-7-methoxy-2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662117-64-8P, 6-Chloro-2-[4-[[di(3-cyanobenzyl)amino]phenyl]-7-methoxy-3H-imidazo[4,5-b]pyridine 662117-67-1P, 3-[[[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]benzonitrile 662117-68-2P, 3-[[[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]benzonitrile trifluoroacetate 662117-69-3P, N-[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide 662117-70-6P, N-[4-(6-Chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide trifluoroacetate 662117-71-7P, 6-Chloro-7-methoxy-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine 662117-72-8P, 6-Chloro-7-methoxy-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-imidazo[4,5-b]pyridine bis(trifluoroacetate) 662117-91-1P, N-[4-(6-Bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl-1H-imidazole-4-sulfonamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridines as Itk kinase inhibitors for use against asthma and allergic rhinitis)


RN 662116-68-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-methoxyphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-69-0 CAPLUS

CN Phenol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 662116-70-3 CAPLUS

CN 3-Pyrrolidinamine, N-[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 662116-72-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-cyclopentyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-80-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-84-9 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 662116-85-0 CAPLUS


CN Benzenemethanol, 3-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 662116-86-1 CAPLUS


CN 1H-imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(2-fluorophenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)






RN 662116-87-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 662116-88-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-(3-ethylphenyl)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-90-7 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl](phenylmethyl)amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-89-4

CMF C27 H30 Cl N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662116-91-8 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 662116-92-9 CAPLUS

CN Ethanol, 2-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-91-8

CMF C20 H24 Cl N5 O3




CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 662116-94-1 CAPLUS  
CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-methyl-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662116-95-2 CAPLUS  
CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 662116-96-3 CAPLUS  
CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[(phenylmethyl)thio]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662116-95-2  
CMF C25 H25 Cl N4 O2 S




CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 662116-97-4 CAPLUS  
CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-N-[4-(methylsulfonyl)phenyl]-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 662116-98-5 CAPLUS  
CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 662116-99-6 CAPLUS  
CN 1,4-Benzenediamine, N'-[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 662117-00-2 CAPLUS

CN Acetamide, N-[4-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-01-3 CAPLUS

CN Acetamide, N-[4-[[6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]amino]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-00-2

CMF C26 H27 Cl N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662117-02-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenoxymethyl- (9CI) (CA INDEX NAME)




RN 662117-04-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 662117-05-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 662117-07-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 662117-12-6 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine-6,7-dicarbonitrile, 2-[4-[2-(4-

morpholinyl)ethoxy]phenyl)- (9CI) (CA INDEX NAME)




RN 662117-14-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carbonitrile, 2-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 662117-19-3 CAPLUS

CN Benzenamine, 5-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 662117-25-1 CAPLUS

CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[[2-(2-pyrrolidinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 662117-26-2 CAPLUS


CN Phenol, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[(2R)-2-pyrrolidinylmethyl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-25-1

CMF C18 H20 Cl N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 662117-28-4 CAPLUS

CN 2-Pyrrolidinemethanamine, N-[5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]phenyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 662117-30-8 CAPLUS  
 CN 1,2-Benzenediamine, 4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-N2-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 662117-31-9 CAPLUS  
 CN Benzenamine, 5-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 662117-33-1 CAPLUS  
 CN 1H-imidazo[4,5-b]pyridine, 6,7-dichloro-2-[4-(4-morpholinyl)phenyl]- (9CI)  
 (CA INDEX NAME)




RN 662117-34-2 CAPLUS

CN Benzenamine, 5-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 662117-38-6 CAPLUS

CN 4-Morpholineethanamine, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 662117-40-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridine, 6-bromo-7-methyl-2-[4-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 662117-43-3 CAPLUS


CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyano- (9CI) (CA INDEX NAME)



RN 662117-44-4 CAPLUS  
 CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-3-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-43-3  
 CMF C20 H14 Br N5 O2 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 662117-45-5 CAPLUS  
 CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano- (9CI) (CA INDEX NAME)



RN 662117-46-6 CAPLUS  
CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-45-5  
CMF C20 H14 Br N5 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 662117-47-7 CAPLUS  
CN 8-Quinolinesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 662117-48-8 CAPLUS  
CN 8-Quinolinesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-47-7  
CMF C22 H16 Br N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-49-9 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 662117-50-2 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-49-9

CMF C20 H17 Br N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-51-3 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)- (9CI) (CA INDEX NAME)




RN 662117-52-4 CAPLUS

CN Benzenesulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-51-3

CMF C22 H18 Br N5 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 662117-54-6 CAPLUS  
 CN 1H-Imidazole-4-sulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-91-1  
 CMF C17 H15 Br N6 O2 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 662117-55-7 CAPLUS  
 CN Benzenesulfonamide, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 662117-56-8 CAPLUS  
 CN Benzenesulfonamide, N-[4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-




yl)phenyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-55-7

CMF C19 H14 Cl2 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 662117-58-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-[4-[[2-(4-morpholinyl)ethyl]amino]phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 662117-59-1 CAPLUS

CN 1H-imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-64-8 CAPLUS

CN Benzonitrile, 3,3'-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]imino]bis(methylene)]bis- (9CI) (CA INDEX NAME)



RN 662117-67-1 CAPLUS

CN Benzonitrile, 3-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 662117-68-2 CAPLUS

CN Benzonitrile, 3-[[[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-67-1

CMF C21 H16 Cl N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-69-3 CAPLUS

CN Benzenesulfonamide, N-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 662117-70-6 CAPLUS

CN Benzenesulfonamide, N-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-4-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-69-3

CMF C20 H14 Cl N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-71-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 662117-72-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 662117-71-7

CMF C20 H23 Cl N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 662117-91-1 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[4-(6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)




IT 662117-32-0, 6-Chloro-2-(4-fluoro-3-nitrophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of imidazopyridines as Itk kinase inhibitors for use against  
asthma and allergic rhinitis)

RN 662117-32-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-2-(4-fluoro-3-nitrophenyl)-7-methyl-  
(9CI) (CA INDEX NAME)




IT 662117-27-3P, tert-Butyl (2R)-2-[[[4-(6-chloro-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)-2-hydroxyphenyl]amino]methyl]pyrrolidine-1-carboxylate 662117-29-5P, 6-Chloro-7-methyl-2-[4-[2-(morpholin-4-yl)ethoxy]-3-nitrophenyl]-3H-imidazo[4,5-b]pyridine 662117-36-4P, 6-Chloro-2-(4-nitrophenyl)-N-phenyl-3H-imidazo[4,5-b]pyridin-7-amine 662117-37-5P, 6,7-Dichloro-2-(4-nitrophenyl)-3H-imidazo[4,5-b]pyridine 662117-57-9P, 4-(6,7-Dichloro-1H-imidazo[4,5-b]pyridin-2-yl)aniline 662117-60-4P, 6-Chloro-2-[4-(2-chloroethoxy)phenyl]-7-methoxy-3H-imidazo[4,5-b]pyridine 662117-61-5P, 2-[4-(6-Chloro-7-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethanol 662117-65-9P, 4-(6-Chloro-7-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)aniline 662117-66-0P, 6-Chloro-7-methoxy-2-(4-nitrophenyl)-3H-imidazo[4,5-b]pyridine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of imidazopyridines as Itk kinase inhibitors for use against  
asthma and allergic rhinitis)

RN 662117-27-3 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-(6-chloro-7-methyl-1H-imidazo[4,5-b]pyridin-2-yl)-2-hydroxyphenyl]amino]methyl]-, 1,1-dimethylethyl ester,  
(2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 662117-29-5 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methyl-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 662117-36-4 CAPLUS  
 CN 1H-imidazo[4,5-b]pyridin-7-amine, 6-chloro-2-(4-nitrophenyl)-N-phenyl-  
 (9CI) (CA INDEX NAME)




RN 662117-37-5 CAPLUS  
 CN 1H-imidazo[4,5-b]pyridine, 6,7-dichloro-2-(4-nitrophenyl)- (9CI) (CA  
 INDEX NAME)



RN 662117-57-9 CAPLUS  
 CN Benzenamine, 4-(6,7-dichloro-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA  
 INDEX NAME)




RN 662117-60-4 CAPLUS  
 CN 1H-imidazo[4,5-b]pyridine, 6-chloro-2-[4-(2-chloroethoxy)phenyl]-7-methoxy-  
 (9CI) (CA INDEX NAME)




RN 662117-61-5 CAPLUS

CN Ethanol, 2-[4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 662117-65-9 CAPLUS

CN Benzenamine, 4-(6-chloro-7-methoxy-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 662117-66-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-chloro-7-methoxy-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:466012 CAPLUS

DOCUMENT NUMBER: 137:47228

TITLE: Preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines as NPY5 receptor activity modulators

INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Darrow, James William; De Lombaert, Stephane; Hutchison, Alan; Tran, Jennifer; Zheng, Xiaozhang; Elliott, Richard Louis; Hammond, Marlys

PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048152	A2	20020620	WO 2001-US47863	20011211
WO 2002048152	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002020276	A	20020624	AU 2002-20276	20011211
US 20030036652	A1	20030220	US 2001-13846	20011211
US 6566367	B2	20030520		
EP 1347982	A2	20031001	EP 2001-270536	20011211
EP 1347982	B1	20051116		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004520299	T	20040708	JP 2002-549683	20011211
BR 2001016113	A	20040803	BR 2001-16113	20011211
AT 310004	T	20051215	AT 2001-270536	20011211
ES 2249384	T3	20060401	ES 2001-270536	20011211
EP 1695977	A2	20060830	EP 2005-16735	20011211
EP 1695977	A3	20060920		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
US 20040072847	A1	20040415	US 2003-410648	20030409
US 6943199	B2	20050913		
MX 2003PA04245	A	20030922	MX 2003-PA4245	20030514
US 20050033048	A1	20050210	US 2003-415457	20030815
US 20060040964	A1	20060223	US 2005-183615	20050718
PRIORITY APPLN. INFO.:			US 2000-254990P	P 20001212
			EP 2001-270536	A3 20011211
			US 2001-13846	A3 20011211
			WO 2001-US47863	W 20011211
			US 2003-410648	A3 20030409

OTHER SOURCE(S): MARPAT 137:47228

GI





AB Title compds. [I; X = O, H<sub>2</sub>; A, D, V, W, Y, Z independently = N, CR<sub>1</sub>; R<sub>1</sub> = H, halo, OH, NH<sub>2</sub>, NO<sub>2</sub>, CN, CONH<sub>2</sub>, COOH; B = N, CR<sub>2</sub>; E = CR<sub>3</sub>; R<sub>2</sub>, R<sub>3</sub> independently = H, halo, OH, NH<sub>2</sub>, NO<sub>2</sub>, CN, CONH<sub>2</sub>, COOH; G = N, NH; J = NH, N; L = bond, CO; dotted bond = single, double] capable of modulating NPY<sub>5</sub> receptor activity are prepared. Such compds. may be used to modulate ligand binding to NPY<sub>5</sub> receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and method for treating such disorders are provided, as are methods for using such compds. for detecting NPY<sub>5</sub> receptors.


IT 438191-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines as NPY<sub>5</sub> receptor activity modulators)

RN 438191-11-8 CAPLUS

CN Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one, 1'-(6-bromo-7-chloro-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.11

217.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.60

-5.60

STN INTERNATIONAL LOGOFF AT 14:07:45 ON 08 APR 2008